Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

vanucizumab 1utomilumab 1selicrelumab 1pembrolizumab 1mogamulizumab 1N-(6,6-dimethyl-5-((1-methylpiperidin-4-yl)carbonyl)-1,4,5,6-tetrahydropyrrolo(3,4-c)pyrazol-3-yl)-3-methylbutanamide 1Fulvestrant 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced/Metastatic Solid Tumors × utomilumab × Clear all
NCT02444793 2019-02-27

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
24 enrolled 34 charts
Other solid neoplasm

Advanced/Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡